Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Osteoprotegerin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:OPG, Osteoclastogenesis inhibitory factor, OCIF, TNFRSF11B, Tumor Necrosis Factor Receptor Superfamily Member 11B
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD194003200 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

35 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1.5–60 pmol/l

Limit of Detection

0.03 pmol/l

Intra-assay (Within-Run)

n = 8; CV = 3.5%

Inter-assay (Run-to-Run)

n = 3; CV = 5.8%

Spiking Recovery

106,70%

Dilutation Linearity

107,60%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • monkey Yes (recommended dilution 1:3)
Summary

Features

  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • The total assay time is less than 3.5 hours
  • The kit measures osteoprotegerin in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism

Summary

Osteoprotegerin (OPG, osteoclastogenesis inhibitory factor, OCIF) is a product of
the TNFRSF11B gene, located on chromosome 8q24. OPG belongs to the TNF (tumor
necrosis factor receptor) superfamily, that plays a key role in bone remodeling. Human OPG
is a secreted glycoprotein composed of 401 aminoacid residues. OPG exists as a disulfidelinked
homodimer (120 kDa) or as a monomer (60 kDa). Both of these forms are active but
the dimer is more bioactive than the monomer. In contrast to most members of the TNF
receptor superfamily, OPG probably exists only in a soluble form. Its ligands are RANKL and
TRAIL. Human OPG shares 85% aminoacid identity to mouse OPG and 86 % identity to rat
OPG. In adult humans OPG mRNA is highly expressed in bones (osteblasts), endothelial
vessel cells, skin, liver, stomach, intestine, heart, brain and lung and is also present
in atherosclerotic plaques.

OPG and RANKL are involved in bone resorption and bone formation. OPG and receptor
RANK compete with each other for binding to the ligand RANKL. Binding of RANKL to RANK
stimulates osteoclasts and their activity. When RANKL binds to OPG, osteoclastogenesis
decreases. OPG prevents the formation of RANKL/RANK, inhibits formation of osteoclasts
and suppress bone resorption.

At normal physiological conditions OPG and ligand RANKL are in balance and bone resorption
and bone formation are linked. This balance can be disrupted by the lack of estrogens
in menopausal women, by anti-inflammatory effect of cytokines and by changes in the level
of glucocorticoids, thyroid hormones, parathyroid hormone or calcitriol. Any modification
in the RANKL/OPG ratio can induce either excessive bone resorption or, in contrast, excessive
bone formation. This disregulation can lead to pathological conditions such as
osteoporosis/osteopenia, bone tumor associated osteolysis, or cardiovascular pathology.
In postmenopausal osteoporosis, OPG serum level decreases and this decrease can be
an indicator of a higher risk for bones fracture. In patients with glucocorticoid induced
osteoporosis the RANKL/OPG ratio was higher. In patients with chronic obstructive pulmonary
disease with low bone mineral density (BMD), RANKL/OPG ratio was significantly higher
compared to those with normal BMD.

Patients with juvenile idiopathic arthritis had significantly lower levels of OPG in serum
and lower OPG/RANKL ratio.
The OPG/RANKL/RANK system affects the cardiovascular system as well. In patients with
ischemic heart disease the serum concentration of OPG was higher than that of healthy
people. In patients with high OPG the risk of cardiovascular mortality is three- or four-times
higher than it is in the healthy population.
Finally, the presence of malignant tumors leads to an inhibition of OPG production resulting
in high bone resorption.
The OPG/RANKL/RANK system affects bone loss in many pathological states and participates
in pathogenesis of vascular diseases. Determination of OPG concentration or RANKL/OPG
ratio is a clinical indicator in the diagnosis of the pathological states mentioned below.

Clinical use and areas of investigation:
Postmenopausal and glucocorticoid induced osteoporosis, Reumatoid arthritis, juvenile idiopathic arthritis, Ischemic heart disease, Diseases with changed bone resorption activity

Product References (72)

References

  • Abd El Dayem SM, Anwar GM, Salama H, Kamel AF, Emara N. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children withcongenital adrenal hyperplasia. Arch Med Sci. 2010 Mar 1;6(1):104-10. doi:10.5114/aoms.2010.13516. Epub 2010 Mar 9. PubMed PMID: 22371729; PubMed CentralPMCID: PMC3278952. See more on PubMed
  • Albu A, Fodor D, Bondor C, Crăciun AM. Bone metabolism regulators and arterialstiffness in postmenopausal women. Maturitas. 2013 Oct;76(2):146-50. doi:10.1016/j.maturitas.2013.07.001. Epub 2013 Aug 1. PubMed PMID: 23916080. See more on PubMed
  • Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HDpatients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant. 2005Mar;20(3):566-70. Epub 2005 Jan 21. PubMed PMID: 15665031. See more on PubMed
  • Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatictype 2 diabetic patients. Diabetes Care. 2005 Sep;28(9):2176-80. PubMed PMID:16123486. See more on PubMed
  • Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonné JF,Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silentmyocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007Nov;30(11):2934-9. Epub 2007 Aug 21. PubMed PMID: 17712025. See more on PubMed
  • Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D.Overexpression of heme oxygenase-1 increases human osteoblast stem celldifferentiation. J Bone Miner Metab. 2010 May;28(3):276-88. doi:10.1007/s00774-009-0134-y. Epub 2009 Nov 19. PubMed PMID: 19924377; PubMedCentral PMCID: PMC3073406. See more on PubMed
  • Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G. Renaltransplantation decreases osteoprotegerin levels. Transplant Proc. 2006Sep;38(7):2317-8. PubMed PMID: 16980077. See more on PubMed
  • Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD.Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate responseto methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016 Oct6;18(1):225. PubMed PMID: 27716324; PubMed Central PMCID: PMC5052933. See more on PubMed
  • Cao H, Wu Y, Li Q, Wu Y, Zhou Q, Røe OD, Chen Y, Wang R, Wang D. SerumsRANKL/OPG predict recurrence after radiofrequency catheter ablation of loneatrial fibrillation. Int J Cardiol. 2014 Jan 1;170(3):298-302. doi:10.1016/j.ijcard.2013.08.084. Epub 2013 Sep 7. PubMed PMID: 24326209. See more on PubMed
  • Cao H, Zhou Q, Wu Y, Li Q, Røe OD, Chen Y, Wu Z, Wang D. Preoperative serumsoluble receptor activator of nuclear factor-κB ligand and osteoprotegerinpredict postoperative atrial fibrillation in patients undergoing cardiac valvesurgery. Ann Thorac Surg. 2013 Sep;96(3):800-6. doi:10.1016/j.athoracsur.2013.04.042. Epub 2013 Jul 16. PubMed PMID: 23870696. See more on PubMed
  • Cao JJ, Johnson LK, Hunt JR. A diet high in meat protein and potential renalacid load increases fractional calcium absorption and urinary calcium excretionwithout affecting markers of bone resorption or formation in postmenopausalwomen. J Nutr. 2011 Mar;141(3):391-7. doi: 10.3945/jn.110.129361. Epub 2011 Jan19. PubMed PMID: 21248199. See more on PubMed
  • Chae SY, Chung W, Kim YH, Oh YK, Lee J, Choi KH, Ahn C, Kim YS. TheCorrelation of Serum Osteoprotegerin with Non-Traditional Cardiovascular RiskFactors and Arterial Stiffness in Patients with Pre-Dialysis Chronic KidneyDisease: Results from the KNOW-CKD Study. J Korean Med Sci. 2018 Dec11;33(53):e322. doi: 10.3346/jkms.2018.33.e322. eCollection 2018 Dec 31. PubMedPMID: 30595681; PubMed Central PMCID: PMC6306329. See more on PubMed
  • Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptoractivator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin inankylosing spondylitis: OPG is associated with poor physical mobility andreflects systemic inflammation. Clin Rheumatol. 2010 Oct;29(10):1155-61. doi:10.1007/s10067-010-1543-y. Epub 2010 Aug 6. PubMed PMID: 20690034. See more on PubMed
  • Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J. Assessment of a serumassay for quantification of abdominal aortic calcification. Arterioscler ThrombVasc Biol. 2006 Nov;26(11):2574-6. PubMed PMID: 17053174. See more on PubMed
  • Dai SM, Nishioka K, Yudoh K. Interleukin (IL) 18 stimulates osteoclastformation through synovial T cells in rheumatoid arthritis: comparison with IL1beta and tumour necrosis factor alpha. Ann Rheum Dis. 2004 Nov;63(11):1379-86.PubMed PMID: 15479886; PubMed Central PMCID: PMC1754791. See more on PubMed
  • di Giuseppe R, Biemann R, Wirth J, Menzel J, Isermann B, Stangl GI, FritscheA, Boeing H, Schulze MB, Weikert C. Plasma osteoprotegerin, its correlates, andrisk of heart failure: a prospective cohort study. Eur J Epidemiol. 2017Feb;32(2):113-123. doi: 10.1007/s10654-016-0172-4. Epub 2016 Jun 15. PubMed PMID:27307249. See more on PubMed
  • Dimitrow PP, Jawień M, Gackowski A. The influence of statins on levels ofcalcification biomarkers in patients with aortic sclerosis or mild aorticstenosis. J Heart Valve Dis. 2011 Jan;20(1):18-22. PubMed PMID: 21404893. See more on PubMed
  • Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin inhemodialysis patients with renal bone disease. Ther Apher Dial. 2009Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x. PubMed PMID: 19379170. See more on PubMed
  • Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T. The effect ofrisedronate treatment on serum cytokines in postmenopausal osteoporosis: a6-month randomized and controlled study. J Bone Miner Metab. 2009;27(4):464-70.doi: 10.1007/s00774-009-0055-9. Epub 2009 Mar 20. PubMed PMID: 19301089. See more on PubMed
  • El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N,Emad Y. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis(TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), andIL-8 with lupus nephritis. J Clin Immunol. 2011 Oct;31(5):848-56. doi:10.1007/s10875-011-9555-1. Epub 2011 Jun 21. PubMed PMID: 21691937. See more on PubMed
  • Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23and osteoprotegerin are independently associated with myocardial damage inchronic kidney disease stages 3 and 4. Another link between chronic kidneydisease-mineral bone disorder and the heart. Nephrol Dial Transplant. 2012Feb;27(2):727-33. doi: 10.1093/ndt/gfr316. Epub 2011 Jul 12. PubMed PMID:21750158. See more on PubMed
  • Friedmann A, Ozmeric N, Bernimoulin JP, Kleber BM, Ayhan E, Aykan T,Gökmenoğlu C. Receptor activator of NF-kappaB ligand (RANKL) and CD 31expressions in chronic periodontitis patients before and after surgery. Cent Eur J Immunol. 2014;39(4):508-17. doi: 10.5114/ceji.2014.47737. Epub 2014 Dec 15.PubMed PMID: 26155171; PubMed Central PMCID: PMC4439964. See more on PubMed
  • García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De laVega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A,Gómez-Rodríguez Mde L. Serum osteoprotegerin and RANKL levels in chronicalcoholic liver disease. Alcohol Alcohol. 2006 May-Jun;41(3):261-6. Epub 2006 Feb13. PubMed PMID: 16476762. See more on PubMed
  • Gogo PB Jr, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Osteoprotegerinis not associated with angiographic coronary calcification. J ThrombThrombolysis. 2006 Dec;22(3):177-83. PubMed PMID: 17111200. See more on PubMed
  • Golledge J, Jayalath R, Oliver L, Parr A, Schurgers L, Clancy P. Relationship between CT anthropometric measurements, adipokines and abdominal aorticcalcification. Atherosclerosis. 2008 Mar;197(1):428-34. Epub 2007 Aug 6. PubMedPMID: 17675038; PubMed Central PMCID: PMC2288671. See more on PubMed
  • González-Reimers E, Alvisa-Negrín J, Santolaria-Fernández F, Ros-Vilamajó R,Martín-González MC, Hernández-Betancor I, García-Valdecasas-Campelo E,González-Díaz A. Prognosis of osteopenia in chronic alcoholics. Alcohol. 2011May;45(3):227-38. doi: 10.1016/j.alcohol.2010.09.002. Epub 2010 Nov 4. PubMedPMID: 21051177. See more on PubMed
  • Gossiel F, Hoyle C, McCloskey EV, Naylor KE, Walsh J, Peel N, Eastell R. Theeffect of bisphosphonate treatment on osteoclast precursor cells inpostmenopausal osteoporosis: The TRIO study. Bone. 2016 Nov;92:94-99. doi:10.1016/j.bone.2016.08.010. Epub 2016 Aug 12. PubMed PMID: 27535783. See more on PubMed
  • Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, TugrulA. Serum osteoprotegerin levels in patients with acute atherothrombotic strokeand lacunar infarct. Thromb Res. 2007;120(4):511-6. Epub 2007 Jan 25. PubMedPMID: 17258300. See more on PubMed
  • Kanzaki H, Chiba M, Sato A, Miyagawa A, Arai K, Nukatsuka S, Mitani H.Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. J Dent Res. 2006 May;85(5):457-62. PubMed PMID: 16632761. See more on PubMed
  • Kim CS, Bae EH, Ma SK, Han SH, Choi KH, Lee J, Chae DW, Oh KH, Ahn C, Kim SW; Representatives of the KNOW-CKD Investigator Group. Association of SerumOsteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights fromthe KNOW-CKD Study. PLoS One. 2016 Nov 17;11(11):e0166792. doi:10.1371/journal.pone.0166792. eCollection 2016. PubMed PMID: 27855207; PubMedCentral PMCID: PMC5113973. See more on PubMed
  • Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, ChoiDS, Choi KM. Serum osteoprotegerin levels are associated with inflammation andpulse wave velocity. Clin Endocrinol (Oxf). 2005 Nov;63(5):594-8. PubMed PMID:16268814. See more on PubMed
  • Kolahi S, Ghorbanihaghjo A, Alizadeh S, Rashtchizadeh N, Argani H, KhabazziAR, Hajialilo M, Bahreini E. Fish oil supplementation decreases serum solublereceptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio infemale patients with rheumatoid arthritis. Clin Biochem. 2010 Apr;43(6):576-80.doi: 10.1016/j.clinbiochem.2009.12.011. Epub 2009 Dec 23. PubMed PMID: 20034487. See more on PubMed
  • Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular RiskFactors and Markers of Atherosclerosis in Stable Kidney Transplant Recipients.Transplant Proc. 2016 Jun;48(5):1543-50. doi: 10.1016/j.transproceed.2015.12.134.PubMed PMID: 27496444. See more on PubMed
  • Krela-Kaźmierczak I, Kaczmarek-Ryś M, Szymczak A, Michalak M,Skrzypczak-Zielińska M, Drwęska-Matelska N, Marcinkowska M, Eder P,Łykowska-Szuber L, Wysocka E, Linke K, Słomski R. Bone Metabolism and thec.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene inPatients with Inflammatory Bowel Disease. Calcif Tissue Int. 2016Dec;99(6):616-624. Epub 2016 Sep 17. PubMed PMID: 27639566; PubMed Central PMCID:PMC5097783. See more on PubMed
  • Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA,Dimopoulou MN, Angelopoulou MK, Pangalis GA. Serum syndecan-1, basic fibroblastgrowth factor and osteoprotegerin in myeloma patients at diagnosis and during thecourse of the disease. Eur J Haematol. 2004 Apr;72(4):252-8. PubMed PMID:15089762. See more on PubMed
  • Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E,Ohanna F, Cristol JP, Rossi M, Leroux JL. Changes in osteoprotegerin/RANKLsystem, bone mineral density, and bone biochemicals markers in patients withrecent spinal cord injury. Calcif Tissue Int. 2005 Jun;76(6):404-11. Epub 2005Apr 11. PubMed PMID: 15812577. See more on PubMed
  • Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM.Increased serum OPG in atrophic nonunion shaft fractures. J Orthop Traumatol.2009 Jun;10(2):55-8. doi: 10.1007/s10195-009-0047-5. Epub 2009 Mar 19. PubMedPMID: 19484355; PubMed Central PMCID: PMC2688591. See more on PubMed
  • Mencej-Bedrac S, Prezelj J, Kocjan T, Teskac K, Ostanek B, Smelcer M, Marc J. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin andtumour necrosis factor superfamily member 11 genes are associated with bonemineral density. J Mol Endocrinol. 2009 Mar;42(3):239-47. doi:10.1677/JME-08-0108. Epub 2009 Jan 8. PubMed PMID: 19131500. See more on PubMed
  • Mora S, Zamproni I, Cafarelli L, Giacomet V, Erba P, Zuccotti G, Viganò A.Alterations in circulating osteoimmune factors may be responsible for high boneresorption rate in HIV-infected children and adolescents. AIDS. 2007 May31;21(9):1129-35. PubMed PMID: 17502723. See more on PubMed
  • Morena M, Bosc JY, Jaussent I, Dupuy AM, Terrier N, Leray-Moragues H, Flavier JL, Maurice F, Delcourt C, Cristol JP, Canaud B. The role of mineral metabolismand inflammation on dialysis vascular access failure. J Vasc Access. 2006Apr-Jun;7(2):77-82. PubMed PMID: 16868901. See more on PubMed
  • Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP,Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006Jan;17(1):262-70. Epub 2005 Nov 9. PubMed PMID: 16280472. See more on PubMed
  • Motovska Z, Vichova T, Tousek P, Dusek L, Widimsky P. Circulatingosteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. Int J Cardiol. 2012 Jul 12;158(2):300-1. doi:10.1016/j.ijcard.2012.04.115. Epub 2012 May 14. PubMed PMID: 22592030. See more on PubMed
  • Najar M, Fayyad-Kazan H, Faour WH, Badran B, Journe F, Lagneaux L. Breastcancer cells and bone marrow mesenchymal stromal cells: a regulated modulation ofthe breast tumor in the context of immune response. Inflamm Res. 2017Feb;66(2):129-139. doi: 10.1007/s00011-016-1000-8. Epub 2016 Oct 25. PubMed PMID:27783097. See more on PubMed
  • Nakahara T, Kawai-Kowase K, Matsui H, Sunaga H, Utsugi T, Iso T, Arai M,Tomono S, Kurabayashi M. Fibroblast growth factor 23 inhibits osteoblastic geneexpression and induces osteoprotegerin in vascular smooth muscle cells.Atherosclerosis. 2016 Oct;253:102-110. doi:10.1016/j.atherosclerosis.2016.08.010. Epub 2016 Aug 20. PubMed PMID: 27599364. See more on PubMed
  • Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serumosteoprotegerin as a determinant of bone metabolism in a longitudinal study ofhuman pregnancy and lactation. J Clin Endocrinol Metab. 2003 Nov;88(11):5361-5.PubMed PMID: 14602774. See more on PubMed
  • Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008Nov;159(5):603-8. doi: 10.1530/EJE-08-0554. Epub 2008 Aug 12. Review. PubMedPMID: 18697793. See more on PubMed
  • Ochiai M, Nakashima A, Takasugi N, Kiribayashi K, Kawai T, Usui K, ShigemotoK, Hamaguchi N, Kohno N, Yorioka N. Vitamin K₂ alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron ClinPract. 2011;117(1):c15-9. doi: 10.1159/000319642. Epub 2010 Aug 3. PubMed PMID:20689320. See more on PubMed
  • Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O. Osteoprotegerin and RANKL serum levels and their relationship with serumghrelin in children with chronic renal failure and on dialysis. Nephron ClinPract. 2007;105(4):c153-8. Epub 2007 Jan 25. PubMed PMID: 17259742. See more on PubMed
  • Öztürk VÖ, Emingil G, Bostanci N, Belibasakis GN. Impact of implant-abutmentconnection on osteoimmunological and microbiological parameters in shortimplants: a randomized controlled clinical trial. Clin Oral Implants Res. 2017Sep;28(9):e111-e120. doi: 10.1111/clr.12937. Epub 2016 Jul 29. PubMed PMID:27469171. See more on PubMed
  • Passeri E, Mazzaccaro D, Sansoni V, Perego S, Nano G, Verdelli C, Lombardi G, Corbetta S. Effects of 12-months treatment with zoledronate or teriparatide onintima-media thickness of carotid artery in women with postmenopausalosteoporosis: A pilot study. Int J Immunopathol Pharmacol. 2019Jan-Dec;33:2058738418822439. doi: 10.1177/2058738418822439. PubMed PMID:30791743; PubMed Central PMCID: PMC6327329. See more on PubMed
  • Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator fornuclear factor kappaB ligand: clinical utility in metabolic bone diseaseassessment. J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. Epub 2005 Aug 16.Review. PubMed PMID: 16105967. See more on PubMed
  • Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significanceof OPG/sRANKL ratio in thalassemia patients suffering from osteopenia orosteoporosis in Egyptian patients. Immunol Invest. 2010;39(8):820-32. doi:10.3109/08820139.2010.498492. Epub 2010 Aug 18. PubMed PMID: 20718662. See more on PubMed
  • Salama HM, El-Dayem SA, Yousef H, Fawzy A, Abou-Ismail L, El-Lebedy D. Theeffects of L-thyroxin replacement therapy on bone minerals and body compositionin hypothyroid children. Arch Med Sci. 2010 Jun 30;6(3):407-13. doi:10.5114/aoms.2010.14264. PubMed PMID: 22371779; PubMed Central PMCID: PMC3282520. See more on PubMed
  • Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels ofosteoprotegerin and receptor activator of NF-kappaB ligand in patients withchronic renal failure. Clin Chem Lab Med. 2007;45(11):1498-503. PubMed PMID:17970704. See more on PubMed
  • Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumornecrosis factor-related apoptosis-inducing ligand as markers of plaqueinstability in coronary artery disease. Angiology. 2010 Nov;61(8):756-62. doi:10.1177/0003319710370961. Epub 2010 May 24. PubMed PMID: 20498140. See more on PubMed
  • Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M.Osteoprotegerin as an independent marker of subclinical atherosclerosis inosteoporotic postmenopausal women. Atherosclerosis. 2009 Jun;204(2):608-11. doi: 10.1016/j.atherosclerosis.2008.10.024. Epub 2008 Oct 31. PubMed PMID: 19062016. See more on PubMed
  • Silva HC, Pinheiro MM, Genaro PS, Castro CH, Monteiro CM, Fonseca FA,Szejnfeld VL. Higher prevalence of morphometric vertebral fractures in patientswith recent coronary events independently of BMD measurements. Bone. 2013Feb;52(2):562-7. doi: 10.1016/j.bone.2012.11.004. Epub 2012 Nov 9. PubMed PMID:23142805. See more on PubMed
  • Skládal P, Jílková Z, Svoboda I, Kolár V. Investigation of osteoprotegerininteractions with ligands and antibodies using piezoelectric biosensors. Biosens Bioelectron. 2005 Apr 15;20(10):2027-34. PubMed PMID: 15741072. See more on PubMed
  • Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJ.Evolution of coronary artery calcification in patients with chronic kidneydisease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2011 Aug;26(8):2582-9. doi: 10.1093/ndt/gfq751. Epub 2011 Jan 11. PubMed PMID:21224493. See more on PubMed
  • Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D.Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc CzechRepub. 2001 Dec;145(2):61-4. Review. PubMed PMID: 12426773. See more on PubMed
  • Stejskal D, Zurek M, Bartek J, Jedelský L, Růzicka V. Osteoprotegerin and bonedensity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001Dec;145(2):75-6. PubMed PMID: 12426776. See more on PubMed
  • Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D, Dupuy AM, CristolJP. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemiain type 2 diabetic patients. Diabetes Care. 2008 Mar;31(3):593-5. Epub 2007 Dec14. PubMed PMID: 18083791. See more on PubMed
  • Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A,Conticello C, Palumbo GA, Di Raimondo F. Effects of imatinib mesylate inosteoblastogenesis. Exp Hematol. 2009 Apr;37(4):461-8. doi:10.1016/j.exphem.2008.12.008. PubMed PMID: 19302920. See more on PubMed
  • Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M,Paraskevopoulos T, Michalea S, Kollia C, Miliou A, Kokkou E, Papavassiliou AG,Stefanadis C. Serum osteoprotegerin and osteopontin levels are associated witharterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013 Sep 1;167(5):1924-8. doi: 10.1016/j.ijcard.2012.05.001. Epub 2012May 27. PubMed PMID: 22640692. See more on PubMed
  • Özden FO, Sakallioğlu EE, Demir E, Bilgici B, Tunçel ÖK, Gökosmanoğlu F,Atmaca A. Effect of bisphosphonate as an adjunct treatment for chronicperiodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand(RANKL) and osteoprotegerin in postmenopausal osteoporosis. J Oral Sci.2017;59(1):147-155. doi: 10.2334/josnusd.16-0241. PubMed PMID: 28367895. See more on PubMed
  • Ulivieri FM, Marchelli D, Como G, Valente G, Messa P, Raimondi AR, Piodi LP.Increased osteoprotegerin in Italian haemodialysis patients. Osteoporos Int. 2006Dec;17(12):1822-3; author reply 1824. PubMed PMID: 17019516. See more on PubMed
  • Vanella L, Kim DH, Asprinio D, Peterson SJ, Barbagallo I, Vanella A, GoldsteinD, Ikehara S, Kappas A, Abraham NG. HO-1 expression increases mesenchymal stemcell-derived osteoblasts but decreases adipocyte lineage. Bone. 2010Jan;46(1):236-43. doi: 10.1016/j.bone.2009.10.012. Epub 2009 Oct 21. PubMed PMID:19853072; PubMed Central PMCID: PMC2818489. See more on PubMed
  • Vezzani G, Quartesan S, Cancellara P, Camporesi E, Mangar D, Bernasek T, DalviP, Yang Z, Paoli A, Rizzato A, Bosco G. Hyperbaric oxygen therapy modulates serumOPG/RANKL in femoral head necrosis patients. J Enzyme Inhib Med Chem. 2017Dec;32(1):707-711. doi: 10.1080/14756366.2017.1302440. PubMed PMID: 28385082;PubMed Central PMCID: PMC6009909. See more on PubMed
  • Garcia Ferrer HR, Azan A, Iraheta I, Von Feldt J, Espinoza LR, Manasson J,Scher JU, Garcia Kutzbach A, Ogdie A. Potential risk factors for reactivearthritis and persistence of symptoms at 2 years: a case-control study withlongitudinal follow-up. Clin Rheumatol. 2018 Feb;37(2):415-422. doi:10.1007/s10067-017-3911-3. Epub 2017 Nov 14. PubMed PMID: 29139030; PubMedCentral PMCID: PMC5776049. See more on PubMed
  • Lee SM, Lee HW, Son YK, Kim SE, An WS. Abdominal aortic calcification scoreamong several vascular calcification scores of plain radiograph is the mostreliable predictor of severe coronary artery calcification in dialysis patients. Ren Fail. 2017 Nov;39(1):729-735. doi: 10.1080/0886022X.2017.1398666. PubMedPMID: 29157086; PubMed Central PMCID: PMC6446146. See more on PubMed
  • Friedrich MJ, Wimmer MD, Schmolders J, Strauss AC, Ploeger MM, Kohlhof H,Wirtz DC, Gravius S, Randau TM. RANK-ligand and osteoprotegerin as biomarkers in the differentiation between periprosthetic joint infection and aseptic prosthesisloosening. World J Orthop. 2017 Apr 18;8(4):342-349. doi: 10.5312/wjo.v8.i4.342. eCollection 2017 Apr 18. PubMed PMID: 28473963; PubMed Central PMCID: PMC5396020. See more on PubMed
  • Bruhn-Olszewska B, Korzon-Burakowska A, Węgrzyn G, Jakóbkiewicz-Banecka J.Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers forCharcot arthropathy development. Sci Rep. 2017 Mar 29;7(1):501. doi:10.1038/s41598-017-00563-4. PubMed PMID: 28356555; PubMed Central PMCID:PMC5428699. See more on PubMed
Summary References (17)

References to Osteoprotegerin

  • Asanuma YF, Shimada Y, Kouzu N, Yokota K, Nakajima K, Sato K, Akiyama Y, Isozaki M, Mikami AS, Kobayashi H, Mimura T. Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol. 2012 May 15;
  • Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Medscape Womens Health. 2000 Mar;5 (2):5
  • Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 Nov;30 (11):2934-9
  • Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res. 2011;12:157
  • Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12 (9):1260-8
  • Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol. 2001;30 (4):229-34
  • Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004 Jul;35 (7):1636-41
  • Gurban CV, Mederle O. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. Rom J Morphol Embryol. 2011;52 (3 Suppl):1113-9
  • Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol. 1999 Sep;141 (3):195-210
  • Kerschan-Schindl K, Mitterbauer M, Fureder W, Kudlacek S, Grampp S, Bieglmayer C, Fialka-Moser V, Pietschmann P, Kalhs P. Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant. 2004 Sep;34 (6):491-6
  • Lien G, Ueland T, Godang K, Selvaag AM, Forre OT, Flato B. Serum levels of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study. Pediatr Rheumatol Online J. 2010;8:30
  • Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005 Jun 14;111 (23):3119-25
  • Morse LR, Nguyen HP, Jain N, Williams S, Tun CG, Battaglino RA, Stashenko P, Garshick E. Age and motor score predict osteoprotegerin level in chronic spinal cord injury. J Musculoskelet Neuronal Inter. 2008 Jan-Mar;8 (1):50-7
  • Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007 Dec;30 (12):3122-4
  • Roysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DA. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012 May;98 (10):786-91
  • Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006 Dec;169 (6):2236-44
  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein i
Related Products Docs